Biological effects of various regimes of 25-hydroxyvitamin D3 (calcidiol) administration on bone mineral metabolism in postmenopausal women

Clinical Cases in Mineral and Bone Metabolism

Volumn 6, Issue 2, 2009, Pages 169-173

  Cavalli, Loredana ^a   Cavalli, Tiziana ^a   Marcucci, Gemma ^a   Falchetti, Alberto ^a   Masi, Laura ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bone biomarkers; Calcidiol; Postmenopausal osteoporosis; Vitamin D3

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIFEDIOL; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; PARATHYROID HORMONE; PHOSPHATE;

AGED; ARTICLE; BIOLOGICAL ACTIVITY; BONE MINERALIZATION; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE URINE LEVEL; DRUG EFFECT; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; URINE LEVEL; VITAMIN SUPPLEMENTATION;

EID: 76249117096     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Utiger RD. The need for more vitamin D. N Engl J Med. 1998;338: 828-829.
2. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocrv Rev. 2001;22:447-501.
3. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
4. Gaugris S, Heaney RB, Boonen S, Kurth H et al. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM. 2005;98:667-676.
5. Kuchuk NO, Van Schoor NM, Pluijm SM, Chines A et al. Vitamin D status, parathyroid function, bone turnover, and BMD in postemenopausal women with osteoporosis: global perspective. J Bone Miner Res. 2009;24(4):693-701.
6. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003 1; 326(7387):469.
7. Togerson D, Donaldson C, Reid D. using economics to prioritize reseatch: A case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy. 1996; 1:141-146.
8. Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol and calcium. N Engi J Med. 1992;326:357-362.
9. Sosa M, Lainez P, Arbelo A, Navarro MC. The effect of 25-hydroxyvitamin D on the bone mineral metabolism of elderly women with hip fractures. Rheumatology. 2000;39:1263-1268.
10. Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987;126:796-802.
11. Cooper C, Campion G, Melton LJ 3rd. Hip fractures In the elderly: a world-wide projection. Osteoporos Int. 1992;2:285-289.
12. Bullamore JR, Wilkinson R, Gallagher JC, Nordin BEC et al. Effect of age on calcium absorption. Lancet 1970;2:535-537.
13. Barragry JM, France MW, Corless D, Gupta SP et al. Clin Sci Mol Med. 1978;55:213-220.
14. Mac Laughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76:1536-1538.
15. lsaia G, Giorgino R, Rini GB, Benlacqua M, et al. Prevalence of hypovitarninosis D in elderly women in Italy: Clinical consequences and risk factors. Osteoporos Int. 2003;14:577-582.
16. Romagnoli E, Caravella P, Scarnecchia L, Martinez P, Minisola S. et al. Hypovitalinosis D In an Italian population of healthy subjects and hospitalized patients. Br J Nutr. 1999;81:133-137.
17. Parfitt AM, Gallagher JC, Heaney RP, Johnston CC et al. Vitamin D and bone health in the elderly. Am J Clin Nutr. 1982;36:805-806.
18. Parfitt AM. Osteomalacia and related disorders. In: Avioli LV, Krane SM (eds) Metabolic bone diseases, 3rd edn. Academic Press, San Diego, pp 327-386.
19. Chapuy MC, Arlot ME, Duboeuf F, Brun J et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637-1642.
20. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
21. Jackson C, Gaugris S, Sen SS, Hosking D. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. Q J Med. 2007;100:185-192.
22. Sahota O, Mundey MK, San P, Godber IM et al. The relationship between vitamin D and parathyroid hormone: calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone. 2004;35:312-319.
23. Compston JE. Vitamin D deficiency: Time for action: Evidence supports routine supplementation for elderly people and others at risk. BMJ. 1998;317:1466-1467.
24. Vieth R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J Ster Biochem Mol Biol. 2004;89-90:575-579.
25. Masud T, Mulcahy B, Thmpson AV, Donnelly S et al. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Ann Rheum Dis. 1998; 57:346-349.
26. Balhorn KE, Baynes KE, Fowler SE, Gallagher JC. The effect of estrogen and calcitriol (Rocaltrol) therapy on calcium metabolism and bone markers in elderly women. J Bone Miner Res. 1998;23: S389.
27. Nuti R, Bianchi G, Brandi ML, Caudarella R et al. Superiorità of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol Int. 2006;26:445-453.
28. Papadimitropoulos E, Wells G, Shea B, Gillispie W et al. The osteoporosis methodology group, and the osteoporosis research advisory group. Meta.analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23:560-569.
29. D'Amore M, Terlizzi N, Matiradonna A, Carrozzo M et al. II 25-idrissi-colecalciferolo nell'osteomalacia delle epatopatie croniche. II Progresso Medico. 1980;5:I-5.
30. Zecca E, Romagnoli C, Alecci MC, Marchili R et al. Prophylaxis of hypocalcemia in the low birth weight newborn. A comparative clinical study of the effectiveness of ergocalciferol and cacifediol. Minerva Pediatr. 1990;42:185-188.
31. Rao DS. Perspective on assessment of vitamin D nutrition. J Clin Densitom. 1999;2:457-464.
32. Kavahara M, Iwasaki Y, Sakaguchi K, Taguchi T et al. Predominant role of 25OHD In the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 2008;82:677-683.
33. Fournier A, Bordier P, Gueris J, Sebert JL et al. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int. 1979;15:196-204.
34. St-Arnaud R, Glorieux FH. 24,25-Dihydroxyvitamin D: active metabolite or inactive catabolite? Endocrinology. 1998;139:3371-3374.
35. Van Leeuwen JP, Van den Bemd GJ, Van Driel M, Buurman CJ. 24,25-Dihydroxyvitamin D(3) and bone metabolism. Steroids. 2001;66(3-5):375-80.
36. Boyan BD, Sylvia VL, Dean DD, Schwartz Z. 24,25-(OH)(2)D(3) regulates cartilage and bone via autocrine and endocrine mechanisms. Steroids. 2001;66(3-5):363-74.
37. Davey DA. Vitamin D and its analogues and the prevention and treatment of osteoporosis. SAMJ. 1997;87:423-425.
38. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842-56.